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Interaction between Vitamin D Receptor
and Vitamin D Ligands: Two-Dimensional
Alanine Scanning Mutational Analysis
vitamin D analogs have been used successfully in the
treatment of calcium and bone disorders and the skin
disorder psoriasis [1]. However, there is still consider-
able interest in academia and the pharmaceutical indus-
try in finding vitamin D-related drugs that exhibit specific
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Although some ambiguities still remain, the structure of
Summary VDR LBD (165–215) has enabled us to analyze ligand
potency on the basis of the structure of the LBD. We
We present a new method to investigate the details of have been studying the structure-function relationship
interaction between vitamin D nuclear receptor (VDR) (SFR) of vitamin D ligands and proposed a simple theory,
and various ligands, namely a two-dimensional alanine the space group concept, on the basis of systematic
scanning mutational analysis. In this method, the conformational analysis of the ligands and their biologi-
transactivation of various ligands is studied in con- cal activities [8–12]. We are now studying the SFR of
junction with a series of alanine scanning mutations vitamin D ligands in connection with their interaction
of the residues lining the ligand binding pocket (LBP) with the VDR. In this paper we suggest a new approach,
of VDR, and the complete set of results is profiled in
two-dimensional analysis. We evaluated the transacti-
a patch table. We investigated examples from four
vation potency of hVDR induced by various vitamin D
structurally diverse groups of known VDR ligands: the
ligands in conjunction with systematic one-point muta-
native vitamin D hormone and two compounds with
tions of the residues forming the ligand binding pocketthe same side chain configuration; four 20-epi com-
(LBP), and the activity profile was analyzed by present-pounds; three 19-nor compounds; and two nonse-
ing the results in a patch table. This profiling of thecosteroids. The patch table of the results indicates
ligand-receptor interaction gives us valuable informa-characteristics of each group in terms of its interaction
tion on the docking mode of the ligands and, in turn,with 18 LBP residues. We demonstrate the validity of
provides insight into modifying the ligand to create vita-this approach by application to docking studies of the
min D drugs with selective function.two nonsecosteroids.
In this paper, we investigated the interaction between
VDR and ligand using 18 one-point mutants of LBP resi-Introduction
dues and 12 ligands: 1,25-(OH)2D3 (1), 22-oxa-1,25-
(OH)2D3 (OCT, 2) [13], 2-hydroxypropoxy-1,25-(OH)2D31,25-dihydroxyvitamin D3 [1,25-(OH)2D3 (1)] is a multi-
(ED71, 3) [14], four 20-epivitamin D analogs (4–7) [10,functional hormone. Besides its classical role in regulat-
15], 2-methylene-19-nor-20-epi-1,25-(OH)2D3 (2MD, 9)ing calcium and phosphorus metabolism, it is involved
[16] and related compounds (8 and 10), and two litho-in such basic functions as regulation of cell proliferation
cholic acid derivatives (11 and 12) [17] (Figure 1). Weand differentiation and the immune response. Active
also used this approach to verify that the 3D structure
of the LBP of the wild-type (wt) VDR is quite similar to*Correspondence: yamada.mr@tmd.ac.jp (S.Y.), yamamoto.mr@
tmd.ac.jp (K.Y.) that of VDR (165–215).
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Figure 1. Chemical Structure of VDR Ligands
Results and Discussion evaluated by dual luciferase assay using a reporter with
a mouse osteopontin (OPN) vitamin D response element
[20]. The assay results are shown in Figure 3. The rolesAlanine Scanning Mutagenesis
Alanine scanning mutation has been used frequently to of individual amino acids, as predicted from the precise
3D structure of hVDR LBD and the current alanine scan-identify functional domains of proteins. We have applied
this technique to probe the atomic level interactions ning mutational analysis, are summarized in Table 1.
Some natural mutants are included for completeness.between amino acid residues forming the LBP of hVDR
and the ligand accommodated in it. We prepared alanine Transactivation-Induced by 1,25-(OH)2D3
Mutation Y143A abolished the transactivation potencymutants of the residues that were predicted to play key
roles (1) in anchoring ligands by hydrogen bonds (Y143, of the VDR. Y143, which is located at the corner of H1
to loop 1–3 and interacts with residues at the -turnD144, S237, R274, S275, S278, C288, H305, H397, and
Q400), (2) in hydrophobic interaction with ligands at the (E277), H4/5 (R274), H1 (H139), and loop 1–3 (Y147),
probably has a significant role in the folding of the LBDside chain (V234, I268 and V300) and at the seco-B- and
C-rings (L233 and W286), and (3) in packing H3 and in addition to its role in anchoring the ligand, forming
a hydrogen bond with the 3-hydroxyl group. TheH4/5 (I271 and V234) and H11 and H12 (Y401), and the
residues that change the conformations between the 3-hydroxyl group of 1,25-(OH)2D3 (1) is within a hydro-
gen bond distance from S278. However, mutation S278Acomplexes with 20-epi vitamin D analogs and the natural
hormone (I238 and I271), viewing the crystal structure of has only a small effect on transactivation [18], indicating
the unimportance of this residue either in the interactionVDR LBD (165–215) [7] (L233A, V234A, S237A, R274A,
S275A, S278A, W286A, C288A, H305A, H397A, Q400A, with the ligand or in protein folding. Mutation D144A
also abolished the transactivation potency of the VDR.and Y401A were reported in the previous paper [18, 19]).
The positions of these mutations are shown in the 3D D144 might have a major role in the folding of the LBD:
its carboxyl group interacts with the main chain NHs ofstructure of VDR LBD (165–215) (Figure 2). The expres-
sion level and stability of these mutants were evaluated T146 and S148 and its main chain carbonyl interacts
with the NH of Y147. It is accepted for many membersby Western blot analysis and confirmed to be similar to
those of the wild-type (Figure 3M) [19]. The transactiva- of the NR family that interaction of H3 and H4/5, either
direct or via the ligand, is important for the LBD to main-tion potencies of these mutants with the natural hor-
mone (1) and 11 other ligands (2–12), including vitamin tain its transcriptionally active conformation [21]. In the
case of the VDR, I271 (H4/5), I238 (H3), and V234 (H3)D analogs and lithocholic acid (LCA) derivatives, were
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Figure 2. Amino Acid Residues Mutated to
Ala in Alanine Scanning Mutation Study
The amino acids mutated to Ala are pre-
sented at their C positions as gray balls in
the VDR-LBD (165–215) (stereoview).
may perform this role: I271 interacts with both I238 and tures of the complexes of these ligands with VDR LBD
(165–215) [7, 22]. However, each group of compoundsV234. Mutation I271A abolished the transcriptional activ-
ity, but the effect of the mutations V234A or I238A was has its own characteristics. These characteristics are
evident when all the results are displayed in one table.moderate. V234 interacts with the ligand at C(22)H2 and
C(24)H2, but I238 does not. Interestingly, I271 and I238
change their side chain conformation concomitantly
when the 20-epivitamin D analogs, 20-epi-1,25-(OH)2D3 Two-Dimensional Analysis of the Complete
Set of Assay Results(MC1288, 4) and 20-epi-22-oxa-24,26,27-trihomo-1,25-
(OH)2D3 (KH1060, 5), are accommodated in the LBP, as To compare the activity spectra of all the ligands and
to identify the characteristics of each compound, weshown by the X-ray structures of VDR LBD (165–215)
complexed with 20-epi-1,25-(OH)2D3 (4) or KH1060 (5) presented the complete set of results in a patch table
(Figure 4). In this table, the columns and rows show[22]. I268 has hydrophobic contacts with C(22)H2 and
C(16)H2 of 1,25-(OH)2D3 (1) in a triangular relationship mutants and ligands, respectively. Ligands are placed
in groups according to their structural similarity, and theand interacts with the residues of H12 (F422) and H11
(H397). Mutation I268A moderately reduced the trans- mutants are ordered so that the more important residues
are placed at the top and the less important residuesactivation potency. The two  methyl groups of V300
interact with C(21)H3 and C(12)H2 of 1,25-(OH)2D3 (1), are at the bottom in terms of the activity induced by
the natural hormone (1). The effects of mutations arebut mutation V300A has only a moderate effect on the
transactivation potency. Mutants not discussed here categorized into four groups for simplicity and are
shown as patches: abolished or significantly reducedhave been described in our previous paper [19] and their
functions are summarized in Table 1. activity (20% of the original activity of wtVDR), solid
patch; moderately reduced (20%–60%), gray; slightlyTransactivation Induced by Other Ligands
We evaluated similarly the transcriptional activities of affected (61%–90%), dotted; and similar or elevated
(91%), unshaded. Inspection of this table leads to the11 VDR ligands. The concentration of the ligand was
changed depending on the activity of each ligand: 20- following conclusions.
First, the upper eight residues (Y143, D144, L233, I271,epi-1,25-(OH)2D3 (4), KH1060 (5), 22-Me-20-epi-1,25-
(OH)2D3 (6), 22-Et-20-epi-1,25-(OH)2D3 (7), 19-nor-20-epi- R274, W286, H397, and Y401) that are essential for the
transactivation of VDR induced by 1,25-(OH)2D3 (1) are1,25-(OH)2D3 (8), and 2MD (9) were assayed at 1010 M;
OCT (2) and 1-hydroxy-2-methylene-19-nor-homopre- also essential for vitamin D ligands with full-length car-
bon chains and the 1-, 25-, and 3-hydroxyl groupsgnacalciferol (1-OH-2M-19-nor-homopregnacalciferol,
10) at 108 M; ED71 (3) at 107 M; and the least active (1–9). Exceptions are 1-OH-2M-19-nor-homopregnacal-
ciferol (10) and LCA (11). 1-OH-2M-19-nor-homopregna-LCA (11) and 3-keto-LCA (12) at 104 M and 3  105 M,
respectively. calciferol (10), which has neither the 25-hydroxyl group
nor its equivalent, needs no hydrogen bond partner inThe activity spectra of the compounds with a 9,10-
secosteroid structure are similar to each other, indicat- the LBP facing the side chain terminal. Therefore, muta-
tion H397A did not show a significant effect on transacti-ing that these compounds are accommodated in the
VDR with a similar docking mode. In fact, the docking vation. Mutation L233A showed only a moderate effect
on the transactivation induced by LCA (11), which hasmode and hydrogen bonding pattern of 1,25-(OH)2D3 (1),
20-epi-1,25-(OH)2D3 (4), and KH1060 (5) in the VDR LBD a 5-cholane structure. L233 plays a key role in binding
the ligand by forming van der Waals contacts with the(165–215) are nearly identical except for their side
chain and D-ring regions, as shown by the X-ray struc- s-cis diene part of vitamin D. Therefore, it is reasonable
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Figure 3. Transcriptional Activities of Wild-Type and 18 One-Point Mutant VDRs Induced by 12 VDR Ligands
(A–L) The results of transactivation assays of 18 mutants stimulated by each of 12 ligands. The activities were evaluated by dual luciferase
assay using a full-length hVDR expression plasmid (pCMX-hVDR) and a luciferase reporter gene with a mouse osteopontin VDRE at the
promoter (SPPx3-TK-Luc) in COS7 cells.
(M) Immunoblot analysis of wild-type and newly mutated VDRs.
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Table 1. Functions of Residues Lining the LBP of hVDR
Amino Acid Natural
1,25-(OH)2D3 Residues Mutant Location Assumed Function
A-ring Y143 H1 Essential for protein folding and/or hydrogen bond with 3-OH
D144 Loop 1–3 Essential for protein folding
S237 H3 Assistant hydrogen bond with 1-OH
R274 R274L H4/5 Hydrogen bond with 1-OH
S275 H4/5 Hydrophobic interaction with ligand
S278 H4/5 Hydrogen bond with 3-OH
C288  sheet Hydrophobic interaction with ligand
B- and C-rings L233 L233fs H3 Hydrophobic interaction with ligand
W286  sheet Hydrophobic interaction with ligand
D-ring and side chain V234 H3 Hydrophobic interaction with ligand and with H4/5
I238 H3 Hydrophobic interaction with H4/5
I268 H4/5 Hydrophobic interaction with ligand
I271 H4/5 Hydrophobic interaction with ligand and with H3
V300 H6 Hydrophobic interaction with ligand
H305 H305Q Loop 6–7 Assistant hydrogen bond with 25-OH
H397 H11 Hydrogen bond with 25-OH
Y401 H11 Hydrophobic interaction with H12
that L233 is not essential for the function of non-9,10- norvitamin D 8 (to give 2MD 9 [23]) enormously elevates
the activity and at the same time reduces the numbersecosteroid ligand LCA (11).
Second, for the transactivation by less bulky ligands, of essential residues to nine. This effect is explained by
recovered hydrophobic interactions at the 2-methyleneimportance of bulky hydrophobic residues increases.
For example, the mutations I238A and I268A significantly group as shown in the docking model of 9 (Figure 5A).
Third, the number of essential residues increases withreduced the activity induced by OCT (2), which has a
less bulky oxygen at the 22-position. For 19-nor-20- a decrease in potency of the ligand. For example, the
A-ring-modified compound ED71 (3) requires additionalepivitamin D (8), which lacks the exocyclic methylene
group that forms key van der Waals contact with L233, six residues. The reason may be that in this compound
compatibility between the receptor and ligand is partiallyan additional six residues are essential. Introduction of
an exocyclic methylene group to the 2-position of 19- destroyed.
Figure 4. Patch Table Presentation of Transactivation Profiles
Whole sets of transcriptional assay results shown in Figure 3 (A–L) are presented in a patch table where the effects of mutations are categorized
in four groups and presented by four kinds of patches: abolished or significantly reduced (20% of the original activity of wtVDR), solid patch;
moderately reduced (20%–60%), gray; slightly affected (61%–90%), dotted; and similar or elevated, unshaded. The columns and rows show
mutants and ligands, respectively.
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Figure 5. Docking Models of VDR Ligands
Vitamin D ligands, 2MD (9) (A), 1-OH-2M-19-
nor-homopregnacalciferol (10) (B), and 22-
Me-20-epi-1,25-(OH)2D3 (6) (D), were docked
into VDR LBD (165–215) (PDB: 1IE9) manu-
ally. LCA (11) (E) and 3-keto-LCA (12) (F) were
docked into VDR LBD (165–215) (PDB:
1DB1) using the docking software FlexX.
(A) Docking model of 2MD 9 showing putative
key hydrophobic interaction of the 2-CH2
group with hydrophobic amino acid residues.
(B) Symmetrical van der Waals contacts be-
tween 1-OH-2M-19-nor-homopregnacalcif-
erol (10) and LBP residues that are assumed
to be responsible for the high potency of this
compound.
(C and D) The interactions of the C(22)H2 of
20-epi-1,25-(OH)2D3 (4) (C, 1IE9) and the 22-
methyl group of 6 (D) with V300 are compared.
(E) LCA (11) docked in the VDR LBP and its
interacting amino acid residues. The side
chain carboxyl group and the 3-hydroxyl
group are within a hydrogen bond distance
from H305 and H397 and S278, respectively.
(F) 3-Keto-LCA (12) docked in the VDR LBP.
The side chain carboxyl group is directed to
the -turn site interacting with S278. The
Connolly channel surface of the VDR LBP is
shown in translucent green (E and F).
Fourth, for highly active 20-epi analogs (4–7), some tant van der Waals contact with the 20-epivitamin D
analogs 4 and 5 at C(22)H2 (Figure 5C). Mutation to lessof the mutations to less bulky residues increase potency,
as indicated by increased unshaded patches. These re- bulky Ala eliminates this important interaction in 4 and
5 but not in the 22-alkyl derivatives 6 and 7, becausesults suggest that highly active compounds have many
van der Waals contacts with the VDR, but conversely the alkyl group at C(22) can still have intense interaction
with V300A. The docking model of 6 (Figure 5D) showsthat these compounds may experience some steric con-
gestion within the LBP. the effect of 22-alkylation on the interaction with V300.
These results clearly explain the reason why 22-alkyl-The activity pattern is characteristic for each type
of compound and affords valuable information about ation has a high potentiation effect. S237 is important
for the group of 19-norvitamin D analogs. Perhaps, toligand receptor interaction and, in turn, about docking
mode. As described above, I238 and I268 are essential compensate the loss of the van der Waals contact at
C(19)H2 with L233, the importance of the hydrogen bondfor the 22-oxa derivative (OCT), suggesting that the hy-
drophobic interaction with I268 is more important in between S237 and the 1-hydroxy group increases. It is
interesting that 1-OH-2M-19-nor-homopregnacalciferolcompound with O(22) than in those with C(22)H2. V300
is important for two 20-epivitamin D analogs (4 and 5), (10) still has transactivation potency similar to that of
the natural hormone. In a docking model of 10 (Figurebecause mutation to Ala abolished transactivation. But
this is not true for the 22-alkylated derivatives (6 and 7), 5B), the short side chain is held very tightly by four
van der Waals contacts at the two symmetrical methylfor which mutation V300A has little effect on potency.
We explain these results as follows. V300 forms impor- groups: the pro-R methyl group contacts H397 and I268,
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and the pro-S methyl group contacts V300 and H305. repulsion between the His and the A-ring. For both LCA
compounds 11 and 12, S278 is important, because bothIn addition to the effect of 2-methylene, this may be the
reason for the unusual potency of the pentanor com- ligands are anchored by hydrogen bonds with this
residue.pound 10.
A striking difference in the activity pattern was found
for the LCA derivatives, new VDR ligands discovered On the Structure of the LBP of Wild-Type hVDR
recently [17]. LCA (11) is a secondary metabolite of bile As described above, Illkirch group has solved the 3D
acid produced by microorganisms present in the intes- structure of the VDR LBD by using a genetically engi-
tine and is thought to be involved in the development neered deletion mutant [7, 22]. Since as many as 51
of colon cancer [24]. Since both LCA (11) and 3-keto- residues are eliminated from loop 1–3, there remain
LCA (12) are nearly 10,000-fold less active than 1,25- some ambiguities for the structure of wtVDR LBD. The
(OH)2D3 (1) in transactivation, it is reasonable that most same authors examined the biological and physico-
residues are essential for transactivation. S278, which chemical properties of VDR LBD (165–215) to answer
is not important for any of the vitamin D ligands tested, the question [27]. They concluded that the eliminated
is essential for both LCA derivatives 11 and 12. Interest- loop is not involved in the main biological function of
ingly, LCA (11) and 3-keto-LCA (12) show different pat- the VDR, and that loop 1–3 in wtVDR is not well ordered
terns in the transactivation. A remarkable difference be- and is highly mobile in solution. In the 2D analysis de-
tween 11 and 12 is found in the mutations S237A and scribed above, we found few discrepancies between the
H305A (Figures 3K and 3L). The transactivation potency transactivation potency displayed by the VDR equipped
of LCA (11) was little affected by the mutation S237A with a full-length loop 1–3 and the results of docking
but was abolished by H305A. On the other hand, 3-keto- studies using the crystal structure of VDR LBD (165–
LCA (12) showed the opposite pattern with these mu- 215).
tants. Additional differences are that L233 is important Recently, the crystal structures of apo- and holo-PXR
for 3-keto-LCA (12) but not so important for LCA (11) LBD have been reported [28]. The PXR is the nuclear
and that Q400 is important for 11 but not very important receptor structurally most closely related to the VDR,
for 12. These differences indicate that the two com- the identity being 44% in the structurally conserved re-
pounds are docked in the LBP with different modes. gion of the LBDs. Although the PXR LBD contains a
We examined the docking of 11 and 12 in VDR LBD long loop between H1 and H3 (Figure 6A), the crystal
(165–215) by using the docking software FlexX [25, 26] structures of both the apo- and holo-forms were eluci-
(Tripos, St. Louis). In this analysis, two docking models dated including this long loop. The 3D structures of the
were suggested for LCA (11), one with the side chain PXR LBD and VDR LBD (165–215) are very similar,
directed to H12 (mode 1, Figure 5E) and the other with excluding those parts covering H6 to the N terminus of
the side chain harbored deep in the -turn site (mode H7. In the PXR LBD, part of the residues of loop 1–3
2). Interestingly, only one docking mode was suggested constitute the bottom of its LBP, but in the crystal struc-
for 3-keto-LCA (12), with the side chain directed to the ture of VDR LBD (165–215), the residues of H6 to H7
-turn site (mode 2, Figure 5F). Considering the marked occupy this position. Therefore, if loop 1–3 of the wtVDR
difference found in the transactivation studies, we as- has a conformation similar to that of the PXR, H6 of the
sume that LCA (11) is docked in the LBP with mode 1 wtVDR would not form the bottom of the LBP, unlike in
(Figure 5E), whereas 3-keto LCA (12) is accommodated VDR LBD (165–215). In that case, the residues V300
with mode 2 (Figure 5F). The docking models coincide (H6) and H305 (H7) would be extruded outside, as for
well with the 2D analysis, as described below. the corresponding residues of the PXR, and would not
VDR LBD (165–215)/LCA (Model 1, Figure 5E) be able to interact with the ligand (Figure 6B). To answer
Mutation S237A has little effect on the potency of LCA this question, we made the six mutants Y143A, I238A,
(11), since S237 is distant from ligand 11 in LCA model S278A, C288A, V300A, and H305A of VDR (165–215)
1. L233 is also situated a little distance from the ligand, and examined their activity by 2D (3  6) analysis with
so its mutation to Ala has only a moderate effect. Q400 three ligands. As shown in Figures 6D and 6E, the wtVDR
at H11 does not have direct contact with VDR ligands, and VDR (165–215) showed nearly the same transacti-
but interacts intimately with L309 (H7) as well as H305 vation pattern, indicating that the LBP structures of the
(loop 6–7), which, in turn, contacts the ligand. Thus, two proteins are similar. These results provide additional
Q400 is important in stabilizing the architecture of the evidence to support the belief that the 3D structure of
VDR LBD. The role of Q400 is not evident when the LBP the wtVDR LBD is nearly identical to that of VDR LBD
residues have intense contact with the docked ligand, (165–215).
as is the case for vitamin D ligands. For the VDR/LCA
complex, where only limited interaction is expected be-
Significancetween the LBP and the ligand, the importance of Q400
would be expected to increase.
Knowledge of precise ligand-receptor interaction isVDR LBD (165–215)/3-keto-LCA (Figure 5F)
crucial for determining the exact function of a ligand.L233 is important for 3-keto-LCA (12), because it is as-
In this paper, we developed a new method to investi-sumed to have intimate interaction with the ligand side
gate the details of a ligand-receptor interaction,chain. Mutation of H305 to less bulky Ala has little effect
namely two-dimensional alanine scanning mutationalon the activity of 3-keto-LCA (12), probably because
analysis in which the activity of various vitamin D li-elimination of a hydrogen bond between H305 and the
3-keto group is compensated by the removal of steric gands in a transient transfection assay was studied in
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Transfection and Transactivation Assayconjunction with a series of alanine scanning muta-
COS-7 cells were cultured in Dulbecco’s modified Eagle’s mediumtions of the residues lining the hVDR LBP; the complete
(DMEM) supplemented with 5% fetal calf serum (FCS). Cells wereset of results was profiled two-dimensionally in a patch
seeded on 24-well plates at a density of 2  104 per well. After 24
table. We investigated examples from four structurally hr, the cells were transfected with a reporter plasmid containing
diverse groups of known VDR ligands by this method: three copies of the mouse osteopontin VDRE (5	-GGTTCAcgaGGT
TCA, SPPx3-TK-Luc), a wild-type or mutant hVDR expression plas-the native vitamin D hormone and two compounds
mid [pCMX-hVDR or pSG5-hVDR (165–215)], and the internal con-with the same side chain configuration; four 20-epi
trol plasmid containing sea pansy luciferase expression constructscompounds; three 19-nor compounds; and two nonse-
(pRL-CMV) by the lipofection method as described previously [18].costeroids. The 12  18 patch table of the results
After 4 hr incubation, the medium was replaced with fresh DMEM
obtained from the assays of 12 ligands with 18 mutants containing 5% charcoal-treated FCS (HyClone, UT). The next day,
led the following conclusions. (1) The eight residues the cells were treated with either the ligand or ethanol vehicle and
cultured for 24 hr. Cells in each well were harvested with a cell lysis(Y143, D144, L233, I271, R274, W286, H397, and Y401)
buffer, and the luciferase activity was measured with a luciferaseare essential for the transactivation by vitamin D li-
assay kit (Toyo Ink, Inc., Japan). Transactivation measured by thegands. (2) Importance of bulky hydrophobic residues
luciferase activity was normalized with the internal control. All exper-increases for the transactivation by less bulky ligands
iments were done in triplicate.
(8, 10–12). (3) The number of essential residues in-
creases with decreasing potency of the ligand (3, 11,
Western Immunoblot Analysis12). (4) Mutations to less bulky residues tend to in-
COS-7 cells maintained in DMEM with 5% FCS were seeded in 60crease the potency of highly active 20-epi-ligands (4–
mm dishes at a density of 8 105 per dish. After 16 hr, the cells were
7). We demonstrated the validity of this approach by transfected with a wild-type or mutant hVDR expression plasmid
correlation with a docking study of the nonsecosteroi- [pCMX-hVDR or pSG5-hVDR (165–215)] by the lipofection method
dal ligands LCA (11) and 3-keto LCA (12). We are devel- as described above. After 4 hr incubation, the medium was replaced
with fresh DMEM containing 1% FCS. Next day the transfected cellsoping this method further to determine the function
were solubilized with Nonidet P-40 (NP-40) lysis buffer (0.5% NP-of H12 in terms of ligand structure, to design new
40, 10 mM Tris-HCl [pH 7.6], 150 mM NaCl, 5 mM EDTA, 2 mMligands with useful function, and to clarify what factors
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 5 
g of aprotinin perallow discrimination among the multiple function of ml). The lysate was diluted 1.3 times in a sample buffer (4% SDS,
this hormone (1). 4% -mercaptoethanol, 125 mM Tris-HCl [pH 6.8], 0.002% BPB,
20% glycerol) and boiled for 2 min. Then 15–20 
g of cellular protein
was loaded on 4%–20% Multi SDS-polyacrylamide gels (Daiichi
Experimental Procedures Pure Chemicals, Tokyo). After electrophoretic fractionation, the pro-
teins were electrotransferred to PVDF transfer membranes (Amer-
Compounds sham, Hybond-P) using a Transblot apparatus (Bio-Rad) in 25 mM
22-Me-20-epi-1,25-(OH)2D3 (6), 22-Et-20-epi-1,25-(OH)2D3 (7) [29], Tris-HCl (pH 7.4), 192 mM glycine, 20% methanol. The membrane
and 19-nor analogs (8–10) [30] were synthesized in our laboratory was blocked by treating with 5% skim milk (Difco) in TBST buffer
by methods as described [10, 16]. OCT (2) and ED71 (3) were kindly (25 mM Tris, 136 mM NaCl, 2 mM KCl, 0.05% Tween 20) for 40 min
gifted by Chugai Pharmaceutical Co., Ltd., and MC1288 (4) and and was washed three times. The membrane was treated with the
KH1060 (5) were kindly gifted by Leo Company. LCA (11) was pur- primary antibody (9A7monoclonal anti-VDR antibody) [32] in TBST
chased, and 3-keto-LCA (12) was synthesized from 11 in our labo- buffer for 40 min and washed four times. The membrane was then
ratory. incubated for 40 min with goat anti-rat IgG HRP-conjugated second-
ary antibody (Santa Cruz) in TBST buffer and washed four times.
hVDR proteins were visualized by chemiluminescence using the
Site-Directed Mutagenesis Chemiluminescence Reagent (NENTM Life Science Products, Inc.)
The human VDR (hVDR) expression vectors, pCMX-hVDR [31] and according to the manufacturer’s instructions.
pSG5-hVDR (165–215) [27], were used as a template for in vitro site-
directed mutagenesis. Point mutants were created using a Quick-
Change Site-directed Mutagenesis Kit (Stratagene, CA). Using syn- Graphical Manipulations and Ligand Docking
Graphical manipulations were performed using SYBYL 6.7 (Tripos,thetic oligonucleotides, six clones of mutated hVDRs (Y143A,
D144A, I238A, I268A, I271A, and V300A) from pCMX-hVDR and an- St. Louis). The atomic coordinates of the crystal structure of hVDR-
LBD (165–215) were retrieved from Protein Data Bank (PDB) (entryother six clones (Y143A, I238A, S278A, C288A, V300A, and H305A)
from pSG5-hVDR (165–215) were produced as described by the 1DB1). Vitamin D analogs were docked into the ligand binding
pocket manually, and LCA (11) and 3-keto LCA (12) were using themanufacturer. E. coli DH5 competent cells were transformed with
the vectors incorporating the desired mutations. The cDNAs of the docking software FlexX (version 1.11.0). FlexX is a fast-automated
docking program that considers ligand conformational flexibility byclones were purified by Qiafilter Plasmid Maxi-Kit (Qiagen, Valencia,
CA), and the presence of the desired mutation was confirmed by an incremental fragment placing technique [25, 26]. The active site,
which is the term equivalent to the LBP used by the docking softwareDNA sequencing.
Figure 6. Comparison of the LBDs of VDR and PXR
(A) Sequence alignment of the LBDs of hVDR and hPXR. Bars above and below the sequences show secondary structures. Identical residues
between the two receptors are shaded in light gray. Residues facing the LBP are presented as boldface letters. Deletion part (S165-P215) of
the VDR for X-ray analysis is boxed with solid line.
(B) Amino acid residues mutated both in the wtVDR and VDR (165–215). The positions of amino acid residues mutated both in the wtVDR
and VDR (165–215) are shown in gray balls at their C on the VDR-LBD (165–215) (gray ribbon), and on this structure, PXR LBD (black
ribbon) is overlaid together with their amino acid residues (C, black balls) at the corresponding sequences to the above VDR residues. Gray
and black labels are those of VDR and PXR, respectively.
(C) Immunoblot analysis of wtVDR, VDR (165–215), and the six one-point mutants of the latter VDR (165–215).
(D and E) Transcriptional activities of six one-point mutants of wtVDR as well as of VDR (165–215) induced by three ligands.
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